Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - SORBS1||intrahepatic cholangiocarcinoma||sensitive||Infigratinib||Case Reports/Case Series||Actionable||In a clinical case study, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-SORBS1 fusion responded to Infigratinib (BGJ398) for 12.6 months before progressing due to acquired FGFR2 K660M and K175R mutations, detected in cell-free DNA (PMID: 31109923).||31109923|